PA
KLRS

Parallel Advisors’s Kalaris Therapeutics KLRS Stock Holding History

Parallel Advisors’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$283 Hold
49
– – ﹤0.01% 3739
2025
Q4 		$414 Hold
49
– – ﹤0.01% 3430
2025
Q3 		$283 Hold
49
– – ﹤0.01% 3404
2025
Q2 		$131 Hold
49
– – ﹤0.01% 3446
2025
Q1 		$393 Sell
49
-1
-2% -$10 ﹤0.01% 3275
2024
Q4 		$481 Hold
50
– – ﹤0.01% 3229
2024
Q3 		$926 Hold
50
– – ﹤0.01% 3056
2024
Q2 		$828 Hold
50
– – ﹤0.01% 3003
2024
Q1 		$864 Hold
50
– – ﹤0.01% 2965
2023
Q4 		$778 Hold
50
– – ﹤0.01% 2992
2023
Q3 		$2.46K Hold
50
– – ﹤0.01% 2750
2023
Q2 		$3.89K Hold
50
– – ﹤0.01% 2525
2023
Q1 		$4.51K Hold
50
– – ﹤0.01% 2446
2022
Q4 		$5.87K Sell
50
-6
-11% -$1.02K ﹤0.01% 2261
2022
Q3 		$10K Buy
56
+6
+12% +$935 ﹤0.01% 2013
2022
Q2 		$4K Hold
50
– – ﹤0.01% 2393
2022
Q1 		$8K Buy
+50
New +$9.97K ﹤0.01% 2140

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Parallel Advisors's KLRS Position: Q1 2026 in Review

Parallel Advisors held its Kalaris Therapeutics (KLRS) position steady in Q1 2026 at 49 shares worth $283. The position accounts for ﹤0.01% of the portfolio, ranked #3739.

Parallel Advisors first reported a position in KLRS in Q1 2022 and has held it in 17 quarters since. The position peaked at $10K in Q3 2022. 58 funds tracked by Wall St. Rank hold KLRS as of Q1 2026.

  • Parallel Advisors held 49 shares of Kalaris Therapeutics worth $283 as of Q1 2026.
  • Parallel Advisors left its Kalaris Therapeutics share count unchanged in Q1 2026.
  • Kalaris Therapeutics made up ﹤0.01% of Parallel Advisors's portfolio in Q1 2026, its #3739 holding.
  • Parallel Advisors first reported a position in Kalaris Therapeutics in Q1 2022 and has held it in 17 quarters since.
  • Parallel Advisors's Kalaris Therapeutics position peaked at $10K in Q3 2022.
  • 58 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q1 2026.

Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.